APA (7th ed.) Citation

Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., . . . Becherel, P. (2023). Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet, 401(10378), 747. https://doi.org/10.1016/S0140-6736(23)00022-3

Chicago Style (17th ed.) Citation

Kimball, Alexa B., et al. "Secukinumab in Moderate-to-severe Hidradenitis Suppurativa (SUNSHINE and SUNRISE): Week 16 and Week 52 Results of Two Identical, Multicentre, Randomised, Placebo-controlled, Double-blind Phase 3 Trials." Lancet 401, no. 10378 (2023): 747. https://doi.org/10.1016/S0140-6736(23)00022-3.

MLA (9th ed.) Citation

Kimball, Alexa B., et al. "Secukinumab in Moderate-to-severe Hidradenitis Suppurativa (SUNSHINE and SUNRISE): Week 16 and Week 52 Results of Two Identical, Multicentre, Randomised, Placebo-controlled, Double-blind Phase 3 Trials." Lancet, vol. 401, no. 10378, 2023, p. 747, https://doi.org/10.1016/S0140-6736(23)00022-3.